ImmunityBio, Inc. IBRX Reportable Segment — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — R&D?
- ImmunityBio, Inc. (IBRX) reported reportable segment — R&D of $67.99M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — R&D changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — R&D increased by 41.0% year-over-year, from $48.23M to $67.99M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — R&D?
- Over 3 years (2022 to 2025), ImmunityBio, Inc.'s reportable segment — R&D has grown at a 5.5% compound annual growth rate (CAGR), from $186.34M to $218.56M.
- What does reportable segment — R&D mean?
- Total spending on research and development for this segment.
- How do you interpret reportable segment — R&D?
- Higher spending indicates a robust pipeline, though it reduces short-term profitability.
- How does reportable segment — R&D compare across companies?
- Standard R&D expense reporting for all life sciences companies.